The major revelation coming out of AbbVie Inc.’s second quarter sales and earnings report, which was largely as expected, was that the firm is abandoning a Phase II tau-targeted Alzheimer’s disease candidate and working to advance a beta-amyloid-targeting agent in clinical development later this year or early in 2022.
Multiple analysts called AbbVie’s change of direction in Alzheimer’s somewhat expected, given the recent US Food and Drug Administration approval...








